The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An Ontario Clinical Oncology Group (OCOG) randomized controlled trial (RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinoma metastases (CAM).
C. Moulton
No relevant relationships to disclose
M. N. Levine
No relevant relationships to disclose
C. Law
No relevant relationships to disclose
R. Hart
No relevant relationships to disclose
L. Ruo
No relevant relationships to disclose
C. Gu
No relevant relationships to disclose
A. Hendler
No relevant relationships to disclose
K. Y. Gulenchyn
No relevant relationships to disclose
M. A. Haider
No relevant relationships to disclose
M. Marcaccio
No relevant relationships to disclose
V. Tandan
No relevant relationships to disclose
D. Quan
No relevant relationships to disclose
D. Jalink
No relevant relationships to disclose
R. Fairfull Smith
No relevant relationships to disclose
S. Hanna
No relevant relationships to disclose
P. D. Greig
No relevant relationships to disclose
M. Husien
No relevant relationships to disclose
T. Finch
No relevant relationships to disclose
J. A. Julian
No relevant relationships to disclose
S. Gallinger
No relevant relationships to disclose